| Literature DB >> 22948409 |
Heng-Fei Luan1, Zhi-Bin Zhao, Qi-Hong Zhao, Pin Zhu, Ming-Yu Xiu, Yong Ji.
Abstract
The JAK2/STAT3 signal pathway is an important component of survivor activating factor enhancement (SAFE) pathway. The objective of the present study was to determine whether the JAK2/STAT3 signaling pathway participates in hydrogen sulfide (H2S) postconditioning, protecting isolated rat hearts from ischemic-reperfusion injury. Male Sprague-Dawley rats (230-270 g) were divided into 6 groups (N = 14 per group): time-matched perfusion (Sham) group, ischemia/reperfusion (I/R) group, NaHS postconditioning group, NaHS with AG-490 group, AG-490 (5 µM) group, and dimethyl sulfoxide (DMSO; <0.2%) group. Langendorff-perfused rat hearts, with the exception of the Sham group, were subjected to 30 min of ischemia followed by 90 min of reperfusion after 20 min of equilibrium. Heart rate, left ventricular developed pressure (LVDP), left ventricular end-diastolic pressure (LVEDP), and the maximum rate of increase or decrease of left ventricular pressure (± dp/dt(max)) were recorded. Infarct size was determined using triphenyltetrazolium chloride (TTC) staining. Myocardial TUNEL staining was used as the in situ cell death detection method and the percentage of TUNEL-positive nuclei to all nuclei counted was used as the apoptotic index. The expression of STAT3, bcl-2 and bax was determined by Western blotting. After reperfusion, compared to the I/R group, H2S significantly improved functional recovery and decreased infarct size (23.3 ± 3.8 vs 41.2 ± 4.7%, P < 0.05) and apoptotic index (22.1 ± 3.6 vs 43.0 ± 4.8%, P < 0.05). However, H2S-mediated protection was abolished by AG-490, the JAK2 inhibitor. In conclusion, H2S postconditioning effectively protects isolated I/R rat hearts via activation of the JAK2/STAT3 signaling pathway.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22948409 PMCID: PMC3854176 DOI: 10.1590/s0100-879x2012007500090
Source DB: PubMed Journal: Braz J Med Biol Res ISSN: 0100-879X Impact factor: 2.590
Figure 1.Schematic diagram depicting the experimental protocol (N = 14). Sham = Time-matched reperfusion; I/R = ischemia/reperfusion; NaHS = sodium hydrosulfide postconditioning; AG-490 = specific inhibitor of JAK2; DMSO = dimethyl sulfoxide.
Left ventricular hemodynamics.
| Group | Baseline | Reperfusion | ||
|---|---|---|---|---|
| 30 min | 60 min | 90 min | ||
| HR (bpm) | ||||
| Sham | 269 ± 11 | 262 ± 19 | 260 ± 18 | 261 ± 19 |
| I/R | 263 ± 12 | 201 ± 20 | 207 ± 28 | 210 ± 26 |
| NaHS | 269 ± 13 | 238 ± 19 | 241 ± 18 | 240 ± 20 |
| NaHS+AG-490 | 276 ± 15 | 211 ± 20 | 218 ± 18 | 220 ± 19 |
| AG-490 | 272 ± 16 | 206 ± 17 | 212 ± 15 | 215 ± 16 |
| DMSO | 264 ± 20 | 210 ± 14 | 214 ± 11 | 220 ± 13 |
| LVEDP (mmHg) | ||||
| Sham | 5.0 ± 0.6 | 5.4 ± 0.7 | 5.2 ± 0.7 | 5.3 ± 0.6 |
| I/R | 4.9 ± 0.4 | 33.1 ± 7.3 | 34.2 ± 7.3 | 33.3 ± 7.1 |
| NaHS | 5.0 ± 0.5 | 26.7 ± 6.1 | 24.2 ± 6.4 | 25.1 ± 6.3 |
| NaHS+AG-490 | 5.2 ± 0.5 | 35.6 ± 5.5 | 35.3 ± 6.1 | 36.0 ± 5.9 |
| AG-490 | 4.9 ± 0.5 | 32.0 ± 5.1 | 32.4 ± 5.9 | 32.5 ± 5.8 |
| DMSO | 5.1 ± 0.6 | 33.1 ± 6.5 | 35.2 ± 6.2 | 34.5 ± 6.0 |
| LVDP (mmHg) | ||||
| Sham | 102 ± 10 | 98 ± 8 | 99 ± 7 | 100 ± 9 |
| I/R | 103 ± 9 | 56 ± 7 | 57 ± 9 | 57 ± 10 |
| NaHS | 97 ± 7 | 73 ± 12 | 75 ± 12 | 74 ± 11 |
| NaHS+AG-490 | 99 ± 8 | 60 ± 9 | 59 ± 9 | 60 ± 9 |
| AG-490 | 101 ± 11 | 61 ± 10 | 62 ± 10 | 61 ± 9 |
| DMSO | 97 ± 8 | 58 ± 9 | 58 ± 10 | 60 ± 10 |
| +dp/dtmax (mmHg/s) | ||||
| Sham | 2731 ± 228 | 2810 ± 180 | 2791 ± 181 | 2800 ± 179 |
| I/R | 2829 ± 239 | 1205 ± 240 | 1220 ± 236 | 1219 ± 230 |
| NaHS | 2790 ± 184 | 1737 ± 177 | 1786 ± 180 | 1801 ± 191 |
| NaHS+AG-490 | 2780 ± 235 | 1136 ± 263 | 1135 ± 272 | 1152 ± 268 |
| AG-490 | 2858 ± 302 | 1223 ± 235 | 1226 ± 247 | 1220 ± 233 |
| DMSO | 2845 ± 182 | 1180 ± 213 | 1195 ± 204 | 1201 ± 211 |
| -dp/dtmax (mmHg/s) | ||||
| Sham | 2098 ± 191 | 2014 ± 192 | 2068 ± 183 | 2072 ± 181 |
| I/R | 2003 ± 197 | 892 ± 195 | 895 ± 190 | 890 ± 191 |
| NaHS | 2001 ± 264 | 1305 ± 204 | 1314 ± 200 | 1318 ± 201 |
| NaHS+AG-490 | 2133 ± 168 | 940 ± 176 | 938 ± 181 | 945 ± 177 |
| AG-490 | 1998 ± 250 | 952 ± 203 | 946 ± 205 | 965 ± 207 |
| DMSO | 2083 ± 176 | 908 ± 188 | 900 ± 190 | 912 ± 192 |
Data are reported as means ± SD (N = 14 for each group). Sham = time-matched reperfusion; I/R = ischemia/reperfusion; NaHS = sodium hydrosulfide postconditioning; AG-490 = specific inhibitor of JAK2; DMSO = dimethyl sulfoxide; HR = heart rate; LVEDP = left ventricular end-diastolic pressure; LVDP = left ventricular developed pressure; +dp/dt = intropy; -dp/dt = lusitropy.
P < 0.05 vs baseline (intragroup comparison).
P < 0.05 vs Sham;
P < 0.05 vs I/R (intergroup comparison) (repeated measures ANOVA).
Figure 2.Percent infarct size of the myocardium at the end of reperfusion. Infarct size was determined using 1% triphenyltetrazolium chloride staining. Eight hearts were used in each group. Data are reported as means ± SD. *P < 0.05 vs Sham; +P < 0.05 vs I/R (one-way ANOVA). For abbreviations of groups, see legend to Figure 1.
Figure 3.Percentage of TUNEL-positive cells in various groups. Six hearts were used in each group. Data are reported as means ± SD. *P < 0.05 vs Sham; +P < 0.05 vs I/R (one-way ANOVA). For abbreviations of groups, see legend to Figure 1.
Figure 4.Western blot analysis. The phosphorylation status of STAT3 (86 kDa) (A), bcl-2 (26 kDa) and bax (21 kDa) (B) was analyzed by Western blot with specific phospho-STAT3 (Tyr705), bcl-2 and bax antibodies at the end of reperfusion. Four hearts were used in each group. Data are reported as means ± SD. *P < 0.05 vs Sham; +P < 0.05 vs I/R; ‡P < 0.05 vs NaHS (oneway ANOVA). For abbreviations of groups, see legend to Figure 1.